AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10096265
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg oral modafinil in the morning and 100 mg at midday
Trial: 7781199
Drug: Methylprednisolone (MP)
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (MP) 0.6 mg/kg IV as Solu‐Medrol
Trial: 6104384
Drug: Somatostatin infusion
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin infusion (500 micrograms/h) with active fungal lipase (150,000 E)
Trial: 6104384
Drug: Somatostatin infusion
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin infusion (500 micrograms/h) with placebo capsules
Trial: 28349328
Drug: Doravirine 100
RxNorm normalized name: doravirine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doravirine 100 mg alone
Trial: 24528997
Drug: School-based inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: School-based inhaled corticosteroid treatment
Trial: 19121451
Drug: Nebivolol monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol monotherapy
Trial: 19121451
Drug: Nebivolol plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol plus diuretic
Trial: 19121451
Drug: Nebivolol plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol plus calcium channel blocker
Trial: 19121451
Drug: Nebivolol plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol plus other antihypertensive medication
Trial: 15879354
Drug: Continuous methimazole
RxNorm normalized name: Methimazole
DrugBank: Methimazole (DB00763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous methimazole (MMI) treatment
Trial: 2065721
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg ketanserin
Trial: 27889366
Drug: Intranasal lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal lidocaine
Trial: 27023009
Drug: Otelixizumab (anti-CD3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Otelixizumab (anti-CD3 monoclonal antibody) administered subcutaneously
Trial: 27023009
Drug: Topical corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroid treatment
Trial: 18204132
Drug: Extra-fine HFA
RxNorm normalized name: Panadol Extra
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extra-fine HFA beclomethasone dipropionate (HFA-BDP) 400 microg twice daily for 7 days followed by 200 microg twice daily for 4 days
Trial: 15785378
Drug: Candesartan treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan treatment for 3 months
Trial: 8585887
Drug: Single 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 30 mg dose of Centchroman (group I, n = 8)
Trial: 8585887
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg Centchroman twice a week for twelve weeks (group II, n = 5)
Trial: 8585887
Drug: Both dosing
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both dosing groups (group I and group II)
Trial: 2162275
Drug: Vasoactive intestinal
RxNorm normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasoactive intestinal peptide (IV infusion)
Trial: 2162275
Drug: Peptide histidine
RxNorm normalized name: Histidine
DrugBank: Histidine (DB00117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peptide histidine valine (IV infusion)
Trial: 2162275
Drug: Peptide histidine
RxNorm normalized name: Histidine
DrugBank: Histidine (DB00117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peptide histidine methionine (IV infusion)
Trial: 2162275
Drug: Vasoactive intestinal
RxNorm normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasoactive intestinal peptide (intra-arterial infusion)
Trial: 2162275
Drug: Peptide histidine
RxNorm normalized name: Histidine
DrugBank: Histidine (DB00117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peptide histidine valine (intra-arterial infusion)
Trial: 2162275
Drug: Vasoactive intestinal
RxNorm normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasoactive intestinal peptide, peptide histidine methionine, peptide histidine valine (IV infusion)
Trial: 375053
Drug: Sequential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment with the same 4 drugs taken singly up to 182 days
Trial: 22610853
Drug: Curcuminoids (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcuminoids (1 g/day)
Trial: 9777083
Drug: Caudal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal morphine 25 micrograms.kg‐1
Trial: 9777083
Drug: Caudal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal morphine 50 micrograms.kg‐1
Trial: 7889959
Drug: Cefprozil 500
RxNorm normalized name: cefprozil 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefprozil 500 mg q. 12 hours
Trial: 7889959
Drug: Cefaclor 500
RxNorm normalized name: cefaclor 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor 500 mg q. eight hours
Trial: 7889959
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil 500 mg q. 12 hours
Trial: 7889959
Drug: Amoxicillin‐clavulanate 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin‐clavulanate 500 mg q. eight hours
Trial: 29595510
Drug: ID93 +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ID93 + GLA-SE (10 μg ID93 + 2 μg GLA-SE)
Trial: 29595510
Drug: ID93 +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ID93 + GLA-SE (2 μg ID93 + 2 μg GLA-SE)
Trial: 29595510
Drug: ID93 +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ID93 + GLA-SE (10 μg ID93 + 5 μg GLA-SE)
Trial: 18510625
Drug: 1-day oral
RxNorm normalized name: ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1-day oral sodium phosphate solution (NaP solution) (1 mL/kg/day, maximum 90 mL in two divided doses; regimen A)
Trial: 18510625
Drug: 3-day magnesium
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-day magnesium citrate (4 mL/kg/day x 3 days, maximum 237 mL, followed by an enema; regimen B)
Trial: 18510625
Drug: 1-day oral
RxNorm normalized name: ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1-day oral sodium phosphate solution (NaP solution) (regimen A)
Trial: 14632796
Drug: Evidence-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evidence-based treatment guidelines for pemphigus vulgaris
Trial: 14719289
Drug: Compound Oldenlandis
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound Oldenlandis Mixture
Trial: 8615060
Drug: Calcipotriol treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol treatment for 6 weeks
Trial: 1091149
Drug: Short-term antibiotic
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term antibiotic prophylaxis regimen with 3 Gm. of cephaloridine in divided doses on the day of operation
Trial: 1091149
Drug: Long-term antibiotic
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term antibiotic prophylaxis regimen with oral cephalexin postoperatively
Trial: 19380134
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) abciximab administration
Trial: 18389773
Drug: Special diet
RxNorm normalized name: Foods for special diets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Special diet consisting of 15 ml/day balsamic vinegar from apples and honey, seabuckthorn berry, rosemary, sage, and basil extracts, 150 g/day whole wheat bread with 2.5% VITAPAN, 15 ml/day grape seed extract rich in polyphenols (gr. 1)
Trial: 15336619
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of alendronate daily + exercise (Al+Ex+)
Trial: 15336619
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg alendronate daily (Al+Ex‐)
Trial: 11519552
Drug: Barium suspension
RxNorm normalized name: barium
DrugBank: Barium (DB12481)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Barium suspension with dynamic viscosity of 320 cPs (G1)
Trial: 11519552
Drug: Barium suspension
RxNorm normalized name: barium
DrugBank: Barium (DB12481)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Barium suspension with dynamic viscosity of 2500 cPs (G2)
Trial: 11519552
Drug: Barium suspension
RxNorm normalized name: barium
DrugBank: Barium (DB12481)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Barium suspension with dynamic viscosity of 3200 cPs (G3)
Trial: 11519552
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CG) with standard barium suspension viscosity of 280 cPs
Trial: 9781930
Drug: Perindopril, 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril, 4 mg o.d. for 6 weeks
Trial: 9781930
Drug: Losartan, 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan, 50 mg o.d. for 6 weeks
Trial: 7828343
Drug: Dopamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine infusion (5 micrograms/kg/min i.v.) for 83-296 hours
Trial: 20837369
Drug: Aleglitazar (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aleglitazar (600 μg/day)
Trial: 16954961
Drug: Whey-predominant study
RxNorm normalized name: whey protein hydrolysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey-predominant study formula (protein/energy ratio: 1.8 g/100 kcal)
Trial: 16954961
Drug: Conventional casein-predominant
RxNorm normalized name: caseins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional casein-predominant formula (protein/energy ratio: 2.6 g/100 kcal)
Trial: 14707568
Drug: Neuromuscular blocking
RxNorm normalized name: Neuromuscular blocking agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuromuscular blocking agents (NMBA)
Trial: 14707568
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy without NMBA (Control group)
Trial: 7965783
Drug: Tandospirone citrate
RxNorm normalized name: Tandospirone
DrugBank: Tandospirone (DB12833)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tandospirone citrate (40, 80 and 160 mg)
Trial: 7965783
Drug: Alprazolam (0.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (0.5, 1.0 and 2.0 mg)
Trial: 2888691
Drug: Intraocular implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraocular implants after intracapsular and extracapsular extraction
Trial: 2888691
Drug: Overall surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall surgery (both treatment modes)
Trial: 29797670
Drug: Imiquimod 5%
RxNorm normalized name: Imiquimod 5% Topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 5% cream (TD group)
Trial: 29797670
Drug: Imiquimod 5%
RxNorm normalized name: Imiquimod 5% Topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 5% cream (FTF group)
Trial: 28823947
Drug: GSK2269557 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2269557 1000 μg
Trial: 28823947
Drug: GSK2269557 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2269557 (various doses: 100, 200, 500, 700, 1000, 2000 μg)
Trial: 17484511
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg DRSP/30 microg ethinyl estradiol (EE)
Trial: 17484511
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg cyproterone acetate (CPA)/35 microg EE
Trial: 9638309
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of Tramal drops (100 mg tramadol-HCl)
Trial: 9638309
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of tramadol (100 mg tramadol-HCl)
Trial: 9638309
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of Tramal drops
Trial: 9638309
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of tramadol
Trial: 7974587
Drug: CC method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC method of measuring carotid stenosis
Trial: 29951768
Drug: Acute cocoa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute cocoa flavanols (530 mg CF, 100 mg epicatechin)
Trial: 26808137
Drug: Low-dose/intensity regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose/intensity regimen of behavior modification (large-group parent training)
Trial: 26808137
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of stimulant medication
Trial: 22784349
Drug: Manasamitra Vataka
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manasamitra Vataka tablets (100 mg twice daily for 30 days)
Trial: 22784349
Drug: Manasamitra Vataka
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manasamitra Vataka tablets (100 mg twice daily for 30 days) + Shirodhara (first 7 days)
Trial: 22784349
Drug: Clonazepam 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonazepam 0.75 mg daily in divided dose for 30 days
Trial: 20409337
Drug: Imiquimod 5%
RxNorm normalized name: Imiquimod 5% Topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 5% cream for 6 weeks (superficial basal cell carcinoma) or 12 weeks (nodular basal cell carcinoma)
Trial: 16086364
Drug: Hydroxyzine HCl
RxNorm normalized name: hydroxyzine HCl
DrugBank: Hydroxyzine (DB00557)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxyzine HCl 30 mg
Trial: 12697867
Drug: High-dose chlorambucil
RxNorm normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose chlorambucil (15 mg/m2/d) plus prednisone (100 mg/d) for 5 days (HD-CHL-P; arm A)
Trial: 12697867
Drug: High-dose chlorambucil
RxNorm normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose chlorambucil (15 mg/m2/d) plus prednisone (100 mg/d) for 5 days plus epirubicin 60 mg/m2 intravenous on day 1 (arm B)
Trial: 12697867
Drug: Interferon alfa
RxNorm normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alfa (IFNalpha-2a; 3 MU, three times weekly) for 12 months
Trial: 10933079
Drug: Children seen
RxNorm normalized name: Pediaclear Childrens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children seen by treatment group physicians.
Trial: 8879895
Drug: IFN‐alpha daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN‐alpha daily for 4 weeks and then intermittently for 20 weeks (total dose, 348 MU)
Trial: 8879895
Drug: IFN‐alpha daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN‐alpha daily for 2 weeks and then intermittently for 22 weeks (total dose, 480 MU)
Trial: 8879895
Drug: IFN‐alpha daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN‐alpha daily for 8 weeks (total dose, 336 MU)
Trial: 30768414
Drug: Combined cognitive‐behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined cognitive‐behavioral and fluoxetine treatment (COMB)
Trial: 28356125
Drug: Group music
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group music therapy offered three times per week in a community centre with a focus on songwriting.
Trial: 27693439
Drug: Chlorhexidine umbilical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine umbilical cord care (10 mL of a 4% chlorhexidine solution applied once per day until 3 days after cord drop)
Trial: 24118830
Drug: Fluvastatin (Lescol®)
RxNorm normalized name: fluvastatin Oral Capsule [Lescol]
DrugBank: Fluvastatin (DB01095)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluvastatin (Lescol®) 40-80 mg
Trial: 24118830
Drug: n-3 PUFA
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 PUFA (Omacor®) high-dose (2-4 g)
Trial: 24118830
Drug: n-3 PUFA
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 PUFA (Omacor®) low-dose (1 g)
Trial: 24118830
Drug: n-3 PUFA
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 PUFA (Omacor®) low-dose + fluvastatin
Trial: 24118830
Drug: n-3 PUFA
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 PUFA (Omacor®) high-dose + fluvastatin
Trial: 24118830
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no active drug)
Trial: 17206633
Drug: Natalizumab (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natalizumab (300 mg) plus infliximab (5 mg/kg)
Trial: 16357613
Drug: Infliximab (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab (5 mg/kg) alone
Trial: 12476481
Drug: Betamethasone dipropionate
RxNorm normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone dipropionate 0.05% cream plus UVB radiation with penicillin
Trial: 12476481
Drug: Betamethasone dipropionate
RxNorm normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone dipropionate 0.05% cream plus UVB radiation without penicillin
Trial: 12476481
Drug: Oral psoralen
RxNorm normalized name: Psoralen
DrugBank: Psoralen (DB18665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral psoralen plus ultraviolet A (PUVA) therapy
Trial: 12476481
Drug: Systemic retinoids
RxNorm normalized name: tocopheryl retinoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic retinoids therapy
Trial: 1793881
Drug: midazolam 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: midazolam 0.3 mg/kg
Trial: 1793881
Drug: thiopental 5
RxNorm normalized name: thiopental 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: thiopental 5 mg/kg
Trial: 1793881
Drug: diazepam 0.4
RxNorm normalized name: diazepam 0.4 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diazepam 0.4 mg/kg
Trial: 6891235
Drug: Eucebral‐N (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eucebral‐N (80 mg etofylline and 100 mg cyclandelate) administered for 4 weeks
Trial: 23219538
Drug: Epididymectomy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epididymectomy with concurrent administration of hyaluronic acid and carboxymethylcellulose (group 1)
Trial: 18470667
Drug: Alendronate monotherapy
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alendronate monotherapy (5 mg/day)
Trial: 18470667
Drug: Vitamin K(2)
RxNorm normalized name: vitamin K 2
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K(2) (45 mg/day) plus alendronate (5 mg/day)
Trial: 18470667
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of vitamin K(2) and alendronate
Trial: 1403077
Drug: Amoxicillin 50mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 50mg/kg/day in three divided doses for 10 days
Trial: 3896885
Drug: nifedipine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nifedipine (30 mg/D)
Trial: 31908254
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine (1.5 mg/kg bolus followed by 1.5 mg/kg/h infusion until 2 h after surgery)
Trial: 31908254
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment with 0.9% saline (equal volume to lidocaine group)
Trial: 28958701
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose (HD) influenza vaccine
Trial: 28958701
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose (SD) influenza vaccine
Trial: 24708676
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care arm (two weekly hours of physical activity training for six weeks).
Trial: 23218157
Drug: Adjunctive ziprasidone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive ziprasidone 60-80 mg
Trial: 23218157
Drug: Adjunctive ziprasidone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive ziprasidone 20-40 mg
Trial: 18573983
Drug: Fee per
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fee per sealant treatment
Trial: 15042614
Drug: Soy isoflavones
RxNorm normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy isoflavones (60 mg)
Trial: 11399692
Drug: Diagnosis of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diagnosis of COPD after oral steroid trial